Drugs / Carbon Nanoparticle Suspension Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04744506 | Nov 2024 → Jul 2028 expected | breast cancer, metastatic malignant neoplasm in the lymph nodes | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carbon Nanoparticle Suspension Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04744506 ↗ |
| Known as | CNSI | “Carbon nanoparticle suspension injection (CNSI) offers a stable and reliable alternative for marking, which could enhance the TAD procedure.” PMID 39402559 ↗ Oct 2024 |